中国批准辉瑞剂用于体重管理,并扩大其代谢性疾病战略。 China approves Pfizer’s ecnoglutide for weight management, expanding its metabolic disease strategy.

中国已批准瑞公司的GLP-1受体激动剂药物ecnoglutide,以Xianweiying的名称销售,用于长期控制超重或肥胖成年人的体重. China has approved Pfizer’s GLP-1 receptor agonist drug ecnoglutide, marketed as Xianweiying, for long-term weight management in overweight or obese adults. 这种每周注射一次的药物已经在中国获得了2型糖尿病的批准, 加入了Novo Nordisk, Eli Lilly和Innovent Biologics的竞争对手. The once-weekly injection, already approved for Type 2 diabetes in China, joins competitors from Novo Nordisk, Eli Lilly, and Innovent Biologics. Pfizer于2026年初从以杭州为基地的Sciwind生物科学公司获得商业化权利。 Pfizer acquired commercialization rights in early 2026 from Hangzhou-based Sciwind Biosciences. 在2025年中国电子商务平台上销售类似药品的强劲势头刺激的需求不断增长的情况下,这项批准标志着辉瑞公司在全球日益关注新陈代谢疾病的战略举措。 The approval marks a strategic move in Pfizer’s expanding global focus on metabolic diseases, amid rising demand fueled by strong 2025 sales of similar drugs on Chinese e-commerce platforms. Pfizer没有披露价格或启动时间表。 Pfizer did not disclose pricing or a launch timeline.